Cargando…

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients

Detalles Bibliográficos
Autores principales:	Bol, Kalijn, van den Bosch, Thomas, Schreibelt, Gerty, Punt, Cornelis, Figdor, Carl, Paridaens, Dion, de Vries, Jolanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646100/ http://dx.doi.org/10.1186/2051-1426-3-S2-P127

Ejemplares similares

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
por: Vasaturo, Angela, et al.
Publicado: (2015)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination
por: Aarntzen, Erik HJG, et al.
Publicado: (2013)

Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?
por: van den Bosch, Thomas, et al.
Publicado: (2010)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
por: Bol, Kalijn F, et al.
Publicado: (2015)

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy
por: Wimmers, Florian, et al.
Publicado: (2014)

Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients
por: Vasaturo, Angela, et al.
Publicado: (2015)

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015)

Chromosomal rearrangements in uveal melanoma: Chromothripsis
por: van Poppelen, Natasha M., et al.
Publicado: (2018)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
por: Bol, Kalijn F., et al.
Publicado: (2016)

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
por: Bol, Kalijn F., et al.
Publicado: (2019)

Absence of Intraocular Lymphatic Vessels in Uveal Melanomas with Extrascleral Growth
por: van Beek, Jackelien G. M., et al.
Publicado: (2019)

FOXD1 Is a Transcription Factor Important for Uveal Melanocyte Development and Associated with High-Risk Uveal Melanoma
por: van den Bosch, Quincy C. C., et al.
Publicado: (2022)

SRSF2 Mutations in Uveal Melanoma: A Preference for In-Frame Deletions?
por: van Poppelen, Natasha M., et al.
Publicado: (2019)

Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4(+) T cells after FcγRII-mediated uptake
por: Benitez-Ribas, Daniel, et al.
Publicado: (2006)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients
por: Aarntzen, EHJG, et al.
Publicado: (2010)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Radiological Patterns of Uveal Melanoma Liver Metastases in Correlation to Genetic Status
por: Yavuzyigitoglu, Serdar, et al.
Publicado: (2021)

The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas
por: Pals, Jan, et al.
Publicado: (2021)

Uveal Melanoma Patients Have a Distinct Metabolic Phenotype in Peripheral Blood
por: de Bruyn, Daniël P., et al.
Publicado: (2023)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Monocyte, macrophage and mast cell-derived PDGF control inflammation, tissue remodelling and autoimmunity in the pathophysiology of Graves’ ophthalmpathy
por: van Steensel, Leendert, et al.
Publicado: (2011)

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma
por: Drabarek, Wojtek, et al.
Publicado: (2022)

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
por: Gorris, Mark A J, et al.
Publicado: (2022)

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
por: Sköld, Annette E., et al.
Publicado: (2015)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E(2) results in high interleukin-12 production and cell migration
por: Boullart, A. C. Inge, et al.
Publicado: (2008)

Fractionated stereotactic radiotherapy for uveal melanoma: Long‐term outcome and control rates
por: van Beek, Jackelien G. M., et al.
Publicado: (2021)

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
por: Laureano, Raquel S, et al.
Publicado: (2022)

Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma
por: de Bruyn, Daniël P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nqomdvot0ljagsqpffnphechrc